-
Nov 12, 2020
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for...
-
Oct 29, 2020
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and...
-
Oct 26, 2020Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and...
-
Oct 15, 2020Upcoming study, to be known as "SWARM-P.a.," is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and...
-
Sep 29, 2020-- Company to Present at Global Gathering of Infectious Disease Leaders and Investors--
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and...
